E-LIB Suche - Ergebnisse für: Schuster, S.J.

1

ECT in a large scale industrial pneumatic conveying system:

Neumayer, M ; Bretterklieber, T ; Suppan, T...
Measurement Science and Technology. 35 (2024) 9 - p. 096002 , 2024

Link: https://doi.org/10.1088/..

2

LONG-TERM DURABLE RESPONSES IN PATIENTS (PTS) WITH RELAPSED..:

Awasthi, R. ; Waldron, E. ; Grupp, S.A....
Cytotherapy. 26 (2024) 6 - p. S152 , 2024

Link: https://doi.org/10.1016/..

3

Seltene Ursache einer progredienten Gangstörung mit rezidiv..:

Klaus, J. ; Schneider, M. ; Rosenkranz, T..
DGNeurologie. 7 (2024) 4 - p. 337-340 , 2024

Link: https://doi.org/10.1007/..

4

Outcomes of diffuse large/high grade B cell lymphoma patien..:

Landsburg, D. J. ; Nasta, S. D. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 448-449 , 2023

Link: https://doi.org/10.1002/..

5

Assessment of Nutrition Knowledge and Considerations Among ..:

Beaty, K. ; Masters, M. ; Battson, M....
Journal of the Academy of Nutrition and Dietetics. 123 (2023) 10 - p. A15 , 2023

Link: https://doi.org/10.1016/..

6

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazin..:

Abramson, J. S. ; Straus, D. ; Bartlett, N....
Hematological Oncology. 41 (2023) S2 - p. 353-355 , 2023

Link: https://doi.org/10.1002/..

7

Combination of everolimus and itacitinib in patients with H..:

Svoboda, J. ; Landsburg, D. L. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 594-595 , 2023

Link: https://doi.org/10.1002/..

8

Outcomes with bendamustine lymphodepletion and brexucabtage..:

Chong, E. A. ; Gerson, J. N. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 528-529 , 2023

Link: https://doi.org/10.1002/..

9

60P Adaptive NK cells as a therapeutic option for childhood..:

Eskandarian, Z. ; Hauch, R.T. ; Spohn, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100533 , 2023

Link: https://doi.org/10.1016/..

10

BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY ..:

Ghilardi, G. ; Paruzzo, L. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 201-201 , 2023

Link: https://doi.org/10.1002/..

11

FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES ..:

Svoboda, J. ; Landsburg, D. L. ; Chong, E. A....
Hematological Oncology. 41 (2023) S2 - p. 35-37 , 2023

Link: https://doi.org/10.1002/..

12

Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-..:

Yegya-Raman, N. ; Wright, C.M. ; Ladbury, C.J....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. S50-S51 , 2023

Link: https://doi.org/10.1016/..

13

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023

Link: https://doi.org/10.1002/..

14

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WI..:

Sehn, L. H. ; Bartlett, N. L. ; Matasar, M....
Hematological Oncology. 41 (2023) S2 - p. 122-125 , 2023

Link: https://doi.org/10.1002/..

15

Health‐related quality of life in patients with relapsed or..:

Maloney, D. G. ; Siddiqi, T. ; Fakhri, B....
Hematological Oncology. 41 (2023) S2 - p. 538-541 , 2023

Link: https://doi.org/10.1002/..